Introduction HR-HPV and C trachomatis (CT) are among the most often diagnosed viral and bacterial STIs in the world, respectively. It has been speculated that both of them might be involved in urogenital carcinogenesis and, moreover, potentiate each other's impact and acquisition. The evidence points to a possible association between CT infection history and increased acquisition of HR-HPV infection was investigated among 173 urologist's office male attendees.

Material and Methods Penile and urethral swabs, and expressed prostate secret were collected from 173 heterosexual men visiting an urologist's office to get routinely tested for STDs in the year of 2009 in St.

Petersburg Only heterosexual men with no HIV, gonorrhoea, syphilis and T vaginalis were enrolled in the study. CT infection was detected by in-house RT-PCR assay in St. Petersburg and confirmed in Amsterdam by a molecular test (TaqMan). The presence of HR-HPV DNA in the studied samples was investigated in Amsterdam by the validated worldwide used GP5+/6+ assay.

Results The results are presented in the Abstract P3-S4.02 table 1. The overall CT and HPV prevalence in the study group was relatively high: 4.6% and 31.2%, respectively. No significant correlations have been found between HR-HPV findings and CT status (p=1.0).

Conclusions Our study demonstrated: (1) CT and HPV prevalence among the Russian population can be high, (2) limited co-infection between HPV and CT infections: HR-HPV types were similarly often detected in both CT+ and CT men, also regardless on their CT acquisition in the past, (3) CT history seems not to increase the HR-HPV acquisition, however, the association between HPV and C trachomatis infection still remains to be elucidated and follow-up studies especially among women or homosexuals. 4) All samples found RT-PCR CT+ in Russia were confirmed CT+ using molecular biological techniques in Amsterdam, showing the validity of CT detection in some settings in St. Petersburg. At the moment we additionally: (1) extent the study group, (2) investigate low-risk HPV detection and (3) perform immunogenetic analyses.